TYRA - Tyra Biosciences, Inc.
NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or the "Company") (NASDAQ: TYRA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Tyra Biosciences, Inc. (“Tyra” or the “Company”) (NASDAQ: TYRA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or the "Company") (NASDAQ: TYRA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Tyra Biosciences, Inc. (“Tyra” or the “Company”) (NASDAQ: TYRA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Shares of Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) have been given a consensus rating of "Moderate Buy" by the fourteen research firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and twelve have given a buy recommendation
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or the "Company") (NASDAQ: TYRA).
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Tyra Biosciences, Inc. (“Tyra” or the “Company”) (NASDAQ: TYRA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
CARLSBAD, Calif., Sept. 14, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the pricing of an underwritten offering of 9,079,000 shares of its common stock at a price of $22.03 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 9,078,529 shares of common stock at a purchase price of $22.029 per share, which equals the offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRAPR NewswireNEW YORK, Sept. 10, 2026NEW YORK, Sept.
NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or the "Company") (NASDAQ: TYRA).
Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBC Transcript
Tyra Biosciences Inc. (NASDAQ:TYRA) stock is trading lower on Wednesday after the company shared initial results from its Phase 2 SURF302 trial evaluating oral dabogratinib, delivering clinical proof of concept and identifying a 60 mg once-daily dose to support planned registrational studies.
Tyra stock plummeted to a 10-month low Wednesday on mixed test results for its experimental bladder cancer treatment.
Tyra Biosciences and Johnson & Johnson are pursuing their own approaches to treating a common, early-stage form of bladder cancer.
CARLSBAD, Calif., Sept. 9, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced initial results from SURF302, its Phase 2 study evaluating oral dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC). The study provided clinical proof of concept for selective oral FGFR3 inhibition and identified 60 mg once-daily (QD) as the potential dose supporting TYRA's planned registrational adjuvant development strategy.
CARLSBAD, Calif., Sept. 8, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced participation at the following investor conference: Cantor Global Healthcare Conference 2026 Format: Virtual fireside chat and one-on-one investor meetingsPresentation Date/Time: Wednesday, September 9, 2026 at 1:00 PM ETLocation: New York, NY A live webcast of the presentation can be accessed by visiting the "For Investors" page on the Tyra Biosciences website and will be available for replay following the event.
Tyra Biosciences is downgraded to "Hold" ahead of key phase 2 SURF302 data for dabogratinib in FGFR3-altered IR-NMIBC patients. Multiple phase 2 readouts, including SURF302, SURF303, and BEACH301, create significant near-term binary risk and opportunity for the company. Company's SNAP platform enables selective FGFR3 targeting, aiming to address efficacy and tolerability gaps left by pan-FGFR inhibitors.
CARLSBAD, Calif., Sept. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that it will host a conference call and webcast on Wednesday, September 9, 2026 at 8:00 am ET to discuss initial clinical results from the SURF302 Phase 2 study evaluating oral dabogratinib for intermediate risk non-muscle invasive bladder cancer (IR NMIBC).
Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) has received a consensus rating of "Moderate Buy" from the fifteen ratings firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have given a buy rating and one has given
Algert Global LLC increased its stake in shares of Tyra Biosciences, Inc. (NASDAQ: TYRA) by 27.2% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 239,120 shares of the company's stock after buying an additional 51,110 shares during the period. Algert Global LLC owned